H-CYTE (OTCMKTS:HCYTD) versus Biotricity (NASDAQ:BTCY) Financial Review

Biotricity (NASDAQ:BTCY) and H-CYTE (OTCMKTS:HCYTD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Volatility & Risk

Biotricity has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Valuation and Earnings

This table compares Biotricity and H-CYTE”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	1.20	-$14.09 million	($0.21)	-2.76
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

H-CYTE has lower revenue, but higher earnings than Biotricity.

Analyst Ratings

This is a summary of current ratings and price targets for Biotricity and H-CYTE, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	1	0	0	2.00
H-CYTE	0	0	0	0	0.00

Insider and Institutional Ownership

3.9% of Biotricity shares are owned by institutional investors. 10.1% of Biotricity shares are owned by insiders. Comparatively, 5.2% of H-CYTE shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Biotricity and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
H-CYTE	-450.40%	N/A	-777.68%

Summary

Biotricity beats H-CYTE on 8 of the 9 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.